Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Neurodegener Dis 2016;16:6-11
(DOI:10.1159/000440841)

Defining the Genetic Architecture of Alzheimer's Disease: Where Next?

Sims R. · Williams J.

Author affiliations

Division of Psychological Medicine and Clinical Neuroscience, Cardiff University School of Medicine, Cardiff, UK

Corresponding Author

Dr. Rebecca Sims

Institute of Psychological Medicine and Clinical Neuroscience

Cardiff University School of Medicine

Cardiff CF24 4HQ (UK)

E-Mail simsrc@cf.ac.uk

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Abstract

Background: Late-onset Alzheimer's disease is a genetically complex disorder. For 17 years, APOE was the only known susceptibility gene for disease. Through mostly genome-wide association studies, 25 loci are now known to associate with late-onset Alzheimer's disease. These susceptibility loci are not randomly distributed with respect to their functions. In fact, pathway analysis implicates significant enrichment of immunity, endocytosis, cholesterol metabolism, and ubiquitination in disease. Summary: Twenty-five loci have now been reliably shown to associate with Alzheimer's disease. However, a significant proportion of genetic variation in disease pathology is yet to be detected. Rare variation is being investigated through exome chip and next-generation sequencing experiments, which have already identified new protective and risk variants. Using a polygenic risk score approach, it is now possible to identify population groups with the greatest and fewest biological susceptibilities to disease. This method has proved more effective in predicting disease status than individual, genome-wide significant variants of small/moderate effect. Future studies will establish the specific functional changes that contribute to disease by piloting novel cellular modelling techniques using reprogrammed induced pluripotent stem cells from individuals with selected risk profiles. This will allow a variety of models to be produced to help understand disease mechanisms and test new drug therapies. Key Messages: Alzheimer's disease is a polygenic trait that has been linked to deficits in immunity, endocytosis, cholesterol metabolism and ubiquitination. Future work will focus on identifying rare disease susceptibility loci, unpicking the functional significance of the known risk loci and piloting novel cellular modelling techniques.

© 2015 S. Karger AG, Basel


References

  1. Wingo TS, Lah JJ, Levey AI, Cutler DJ: Autosomal recessive causes likely in early-onset Alzheimer disease. Arch Neurol 2012;69:59-64.
  2. Hardy J: The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem 2009;110:1129-1134.
  3. Gatz M, et al: Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 2006;63:168-174.
  4. Strittmatter WJ, et al: Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993;90:1977-1981.
  5. Colhoun HM, McKeigue PM, Davey Smith G: Problems of reporting genetic associations with complex outcomes. Lancet 2003;361:865-872.
  6. Harold D, et al: Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009;41:1088-1093.
  7. Lambert J-C, et al: Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009;41:1094-1099.
  8. Seshadri S, et al: Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 2010;303:1832-1840.
  9. Hollingworth P, et al: Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 2011;43:429-435.
  10. Naj AC, et al: Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 2011;43:436-441.
  11. Lambert JC, et al: Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 2013;45:1452-1458.
  12. Liu F, et al: A study of the SORL1 gene in Alzheimer's disease and cognitive function. J Alzheimers Dis 2009;18:51-64.
  13. Escott-Price V, et al: Gene-wide analysis detects two new susceptibility genes for Alzheimer's disease. PLoS One 2014;9:e94661.
  14. Ruiz A, et al: Follow-up of loci from the International Genomics of Alzheimer's Disease Project identifies TRIP4 as a novel susceptibility gene. Transl Psychiatry 2014;4:e358.
  15. Cruchaga C, et al: Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease. Nature 2014;505:550-554.
  16. Karch CM, Cruchaga C, Goate AM: Alzheimer's disease genetics: from the bench to the clinic. Neuron 2014;83:11-26.
  17. Hooli BV, et al: PLD3 gene variants and Alzheimer's disease. Nature 2015;520:E7-E8.
  18. Lambert J-C, et al: PLD3 and sporadic Alzheimer's disease risk. Nature 2015;520:E1.
  19. Van der Lee SJ, et al: PLD3 variants in population studies. Nature 2015;520:E2-E3.
  20. Heilmann S, et al: PLD3 in non-familial Alzheimer's disease. Nature 2015;520:E3-E5.
  21. Cruchaga C, Goate AM: Cruchaga and Goate reply. Nature 2015;520:E5-E6.
  22. Peng Q, et al: The MTHFR C677T polymorphism contributes to increased risk of Alzheimer's disease: evidence based on 40 case-control studies. Neurosci Lett 2015;586:36-42.
  23. Mansouri L, et al: Association of methylenetetrahydrofolate reductase polymorphisms with susceptibility to Alzheimer's disease. Clin Neurol Neurosurg 2013;115:1693-1696.
  24. Lu Y, et al: Quantitative assessment of CYP2D6 polymorphisms and risk of Alzheimer's disease: a meta-analysis. J Neurol Sci 2014;343:15-22.
  25. So H-C, Gui AH, Cherny SS, Sham PC: Evaluating the heritability explained by known susceptibility variants: a survey of ten complex diseases. Genet Epidemiol 2011;35:310-317.
  26. Ridge PG, Mukherjee S, Crane PK, Kauwe JSK: Alzheimer's Disease: Analyzing the Missing Heritability. PLoS One 2013;7:e79771.
  27. McCarthy MI, et al: Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet 2008;9:356-369.
  28. Guerreiro R, et al: TREM2 variants in Alzheimer's disease. N Engl J Med 2013;368:117-127.
  29. Jonsson T, et al: Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 2013;368:107-116.
  30. Jonsson T, et al: A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 2012;488:96-99.
  31. Mayeux R, et al; Alzheimer's Disease Genetics Consortium. A rare mutation in UNC5C predisposes to late-onset Alzheimer's disease and increases neuronal cell death. Nat Med 2014;20:1452-1457.
  32. Korvatska O, et al: R47H variant of TREM2 associated with Alzheimer disease in a large late-onset family: clinical, genetic, and neuropathological study. JAMA Neurol 2015;72:920-927.
  33. Kim M, et al: Potential late-onset Alzheimer's disease-associated mutations in the ADAM10 gene attenuate α-secretase activity. Hum Mol Genet 2009;18:3987-3996.
  34. Kim JH, et al; Alzheimer's Disease Neuroimaging Initiative: Gene-based rare allele analysis identified a risk gene of Alzheimer's disease. PLoS One 2014;9:e107983.
  35. Logue MW, et al; Alzheimer Disease Genetics Consortium: Two rare AKAP9 variants are associated with Alzheimer's disease in African Americans. Alzheimers Dement 2014;10:609-618.
  36. International Genomics of Alzheimer's Disease Consortium (IGAP): Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimers Dement J Alzheimers Assoc 2015;11:658-671.
  37. Lee SH, et al: Estimation and partitioning of polygenic variation captured by common SNPs for Alzheimer's disease, multiple sclerosis and endometriosis. Hum Mol Genet 2013;22:832-841.
  38. Escott-Price V, et al: Common polygenic variation can contribute to risk prediction of Alzheimer's disease. Brain 2015, Epub ahead of print.
  39. Combarros O, Cortina-Borja M, Smith AD, Lehmann DJ: Epistasis in sporadic Alzheimer's disease. Neurobiol Aging 2009;30:1333-1349.

Article / Publication Details

First-Page Preview
Abstract of Review

Received: June 02, 2015
Accepted: September 03, 2015
Published online: November 10, 2015

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 1

ISSN: 1660-2854 (Print)
eISSN: 1660-2862 (Online)

For additional information: https://www.karger.com/NDD